A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
Exelixis, Inc. determined the insertion site of P{XP}d09477 to be Release 3 genomic coordinate 9423408 on chromosome arm 3L, which corresponds to Release 5 coordinate 3L:9458979 . The insertion site of PBac{WH}fryf01845 is Release 5 genomic coordinate 3L:9671802 . Consequently, the molecular breakpoints of Df(3L)BSC773 predicted from the Release 5 genomic coordinates of the transposable element insertion sites are 3L:9458979 ;9671802 and the cytological breakpoints predicted from these coordinates are 67B8;67C4.